Tyrosine kinase inhibitors combined with PD-1 inhibitors reduce peritoneal metastasis risk for patients with ruptured HCC receiving TACE/TAE: a multicenter retrospective study | Synapse
April 12, 2026Open Access
Tyrosine kinase inhibitors combined with PD-1 inhibitors reduce peritoneal metastasis risk for patients with ruptured HCC receiving TACE/TAE: a multicenter retrospective study
Key Points
The aim is to evaluate the efficacy of combining tyrosine kinase inhibitors with PD-1 inhibitors in reducing peritoneal metastasis risk in patients with ruptured hepatocellular carcinoma undergoing TACE/TAE.
Multicenter retrospective study design
Comparison of outcomes between TKI + PD-1 inhibitors and TACE/TAE treatments
Focus on patients with ruptured HCC, particularly HBV-related and BCLC C types
Combination therapy significantly reduced the risk of peritoneal metastasis compared to TACE/TAE alone
Lower occurrence of peritoneal metastasis noted in patients with HBV-related ruptured HCC
Findings suggest a beneficial effect of the dual treatment approach in high-risk populations
Abstract
The combination of TKIs and PD-1 inhibitors reduced the risk of PM compared with TACE/TAE in patients with ruptured HCC. Also, PM was less likely to occur in patients with HBV-related and BCLC C ruptured HCC.